In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Value of Me-Too's in the Context of OTC Switches

Executive Summary

At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.

Related Content

Shaking Up the FDA
WellPoint: Revitalizing Managed Care
Big Pharma Continues to Rely on Marketing to Consumers
Kimono Openings at Schering
Keeping the Workforce: the Drug Industry's Cognitive Dissonance Problem
Pharma Future: Is the Glass Half-Empty or Half-Full
Schering-Plough's About-Face On OTC Claritin
Schering-Plough's About-Face On OTC Claritin
Pharma Future: Is the Glass Half-Empty or Half-Full
AstraZeneca: Bridging the Prilosec Earnings Gap


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts